Search

Displaying results 3401 - 3410 of 10000 in total
  1. Drug

    Insulin pork

    go.drugbank.com/drugs/DB00071
    Approved

    Insulin isolated from pig pancreas. Composed of alpha and beta chains, processed from pro-insulin. Forms a hexameric structure.

    Categories: Drugs Used in Diabetes
  2. Drug

    L-deprenyl-D2 C-11

    go.drugbank.com/drugs/DB12650
    Experimental

    L-deprenyl-D2 C-11 is under investigation in clinical trial NCT01701089 (A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers).

    Synonyms: (11C)L-deprenyl-D2, L-deprenyl-D2 C-11
  3. Drug

    Influenza A virus A/Darwin/9/2021 IVR-228 (H3N2) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB16924
    ApprovedWithdrawn

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  4. Drug

    Influenza A Virus A/Sydney/5/2021 SAN-013 (H1N1) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB17751
    ApprovedWithdrawn

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  5. Drug

    Influenza A Virus A/Victoria/4897/2022 IVR-238 (H1N1) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB17994
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  6. Drug

    Influenza A virus A/Victoria/4897/2022 IVR-238 (H1N1) Antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB17997
    ApprovedWithdrawn

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  7. Drug

    Influenza A virus A/Thailand/8/2022 IVR-237 (H3N2) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB19320
    ApprovedWithdrawn

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  8. Drug

    Influenza A virus A/Croatia/10136RV/2023 X-425A (H3N2) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB22670
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  9. Drug

    Influenza A virus A/Croatia/10136RV/2023 X-425A (H3N2) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB22672
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  10. Drug

    Vonicog alfa

    go.drugbank.com/drugs/DB12872
    ApprovedInvestigational

    [A264389] Vonicog alfa works to reduce bleeding events and bleeding times in patients with vWD, who have deficiencies in VWF.[A264389] … [A264444] Used to treat von Willebrand Disease (vWD), it mimics the biological actions of endogenous VWF,[L51274] which is a critical plasma glycoprotein involved in platelet adhesion and aggregation.

    Synonyms: (618-THREONINE,709-ASPARTIC ACID)VON WILLEBRAND FACTOR HOMO SAPIENS (1381A>T,1472H>D VARIANT) BLOOD COAGULATION FACTOR